Home > Boards > US Listed > Biotechs > Stemline Therapeutics (STML)

HUGE NEWS

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
cashcow3 Member Profile
 
Followed By 11
Posts 801
Boards Moderated 0
Alias Born 04/09/14
160x600 placeholder
Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in Systemic Sclerosis, an Autoimmune ... GlobeNewswire Inc. - 6/17/2019 7:30:00 AM
Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp) Clinical Presentations at EHA Congress June 13-15 GlobeNewswire Inc. - 6/13/2019 7:30:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 6/11/2019 5:03:08 PM
Notice of Exempt Solicitation. Definitive Material. (px14a6g) Edgar (US Regulatory) - 6/11/2019 3:44:59 PM
Stemline Therapeutics Announces ASCO Presentation of ELZONRIS Phase 2 Clinical Data in CMML and MF; Provides Next Steps for C... GlobeNewswire Inc. - 6/3/2019 7:30:00 AM
Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress GlobeNewswire Inc. - 5/20/2019 7:00:00 AM
Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at the Upcoming ASCO Annual Meeting GlobeNewswire Inc. - 5/16/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2019 4:17:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/10/2019 7:31:17 AM
Stemline Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire Inc. - 5/10/2019 6:30:00 AM
Stemline Therapeutics to Host Conference Call on First Quarter 2019 Financial Results on May 10, 2019 GlobeNewswire Inc. - 5/8/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 5/2/2019 6:03:32 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/30/2019 5:22:44 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/30/2019 5:20:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/29/2019 8:33:42 AM
Stemline Therapeutics Announces New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study Results GlobeNewswire Inc. - 4/25/2019 7:00:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/19/2019 5:02:16 PM
Stemline Therapeutics to Participate in Panel on Myeloid Tumors at the 31st Annual ROTH Conference GlobeNewswire Inc. - 3/18/2019 7:00:00 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 3/15/2019 5:10:18 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/15/2019 4:21:11 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/15/2019 4:11:11 PM
Stemline Therapeutics Reports Fourth Quarter 2018 Financial Results GlobeNewswire Inc. - 3/15/2019 4:01:00 PM
Stemline Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference GlobeNewswire Inc. - 3/6/2019 7:30:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/22/2019 4:40:14 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/14/2019 10:19:52 AM
cashcow3   Thursday, 03/23/17 08:00:36 AM
Re: None
Post # of 49 
HUGE NEWS

Completes Stage 3 Enrollment
Stemline has completed enrollment of the Stage 3 cohort of the SL-401 pivotal trial in BPDCN. Stage 3 enrolled 13 first-line BPDCN patients; statistical analysis will be based on evaluable first-line patients. The registration pathway was previously agreed upon with the U.S. Food and Drug Administration (FDA). Depending on the data from the trial, Stemline plans to use the results generated to support the potential filing of a Biologics License Application (BLA) for full approval in first-line BPDCN, and is targeting possible BLA filing in the second half of this year.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist